News

BlackBerry's QNX software has secured new deployments in industrial automation, robotics, and medical AI. The QNX platform is being adopted in a new AI powered heart pump developed by Johnson & Johnson. These wins extend QNX beyond its traditional automotive base into additional embedded and safety critical use cases. For investors watching TSX:BB, this QNX expansion comes with the stock at CA$12.86 and strong recent momentum. The share price is up 51.3% over the past 30 days, 146.4% year...

A Super Bowl weekend is one of the most in-demand and expensive recurring trips in American life. Tickets, airfare, hotels, meals, and ground transportation commonly run $8,000 to $15,000 per couple, so a realistic annual budget lands near $12,000. Can your portfolio can pay for one every February without ever touching principal? That is the work ... A $650,000 Portfolio That Could Send You to the Super Bowl Every Year

Paying $2,000 a month in rent is often described as throwing money away. Homeownership, by contrast, is treated as the only reliable path to wealth. Yet under the right conditions, a dividend portfolio large enough to cover your rent can leave you with greater flexibility and, in some cases, a larger net worth than owning ... Why a Dividend Portfolio That Pays Your Rent May Beat Homeownership by $500,000 Over 20 Years

Johnson & Johnson (NYSE:JNJ) is one of the 7 Best Longevity Stocks to Buy Now. On June 8, 2026, Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Firefly Bio, Inc. for $1B in cash. Firefly Bio is advancing its proprietary Firelink degrader antibody conjugate platform, which is focused on KRAS-driven tumors. Johnson […]

Johnson & Johnson (JNJ) closed at $240.87 in the latest trading session, marking a +1.07% move from the prior day.

While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.

Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.

Medical science's capabilities are catching up with what it knows about the genomics of disease. J&J just made sure it's better equipped to utilize the industry's newest capabilities.

Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.

Twelve thousand dollars a month in dividend income sounds simple enough until you start doing the math. Many investors assume they can reach that number with a seven-figure portfolio and a handful of high-yield stocks. In reality, the capital required ranges from about $1.4 million to more than $4 million, depending on the yield you ... How to Build $12,000 a Month in Dividend Income (And Why Most Investors Underestimate the Cost)

Johnson & Johnson (NYSE:JNJ) was among the stocks Jim Cramer commented on, saying that tech stocks cannot be trusted to lead anymore. Cramer mentioned the company while highlighting his current sentiment around drug stocks, as he remarked: Obviously, the other leadership groups are a little more palatable to me… Healthcare, eureka, I found it. This […]

Guinness Global Innovators, an investment management company, recently released its Q1 2026 quarterly investor update for its “Guinness Global Equity Income Fund”. A copy of the letter is available to download here. The Fund focuses on providing investors with global exposure to dividend-paying companies. In Q1 2026, the fund returned was -0.5% (GBP), compared to -1.6% […]

A $50,000 dividend income stream looks unimpressive next to a $100,000 high-yield payout. Twenty years later, the comparison may look very different. That is the entire case for dividend growth investing. The goal is not to maximize income in year one. It is to build an income stream that can keep growing long after a ... The Dividend Growth Strategy That Turns $50,000 a Year Into $125,000 Without Investing Another Dollar

If you own JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI), you bought it for a reason that still holds. JEPI pays monthly. It leans on a defensive equity sleeve and runs a covered call overlay that turns volatility into income. It is the largest active ETF in the country, yielding near 8.2%. But a younger competitor now runs the same ... Forget JEPI, Goldman’s S&P Income ETF Has Beaten It by 42 Points Since Launch

New cancer therapies may help fund dividend growth.

Is JNJ a good stock to buy? We came across a bullish thesis on Johnson & Johnson on Dividend School’s Substack by School of Investing. In this article, we will summarize the bulls’ thesis on JNJ. Johnson & Johnson’s share was trading at $237.00 as of June 9th. JNJ’s trailing and forward P/E were 26.97 and 20.12 […]

Event overview and recent stock performance Johnson & Johnson (JNJ) has drawn fresh attention after recent share price moves, with the stock up about 7.7% over the past month and roughly 15% year to date. See our latest analysis for Johnson & Johnson. The recent 7.7% 30 day share price return, alongside a 15.0% year to date share price return and a 1 year total shareholder return of 57.4%, points to momentum building as investors reassess Johnson & Johnson’s long term prospects and risk...

Before the stock surged, management was laying out a multi-billion-dollar growth story that directly contradicted consensus estimates, if you knew where to look.

Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.

A Utah couple with two children and four grandchildren nearby has a retirement goal that has nothing to do with yachts or sports cars. They want to be the grandparents who can say “yes.” Yes to helping with travel hockey. Yes to a week at the lake. Yes to Disney. Yes to contributing toward a ... The Retirement Portfolio for Grandparents Who Want to Say Yes

I keep buying Johnson & Johnson (NYSE:JNJ) because the market keeps handing me a discount on a company that refuses to act like the slow, sleepy legacy name Wall Street wants to price it as. The Fed will say what it says this month. The headlines will do what headlines do. I am still hitting ... The Fed Is Poised to Shake Wall Street This Month: Here Is the 1 Dirt-Cheap Stock I’m Loading Up on Anyway

ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.

Rare Autoimmune Disease Could Become New Growth Opportunity

With the rate environment stabilizing in mid-2026, income investors are circling back to a familiar playbook: own the businesses that have raised payouts through every cycle in living memory. Dividend Kings and Aristocrats with 25-plus years of consecutive hikes offer a growing cash payment backed by durable franchises that the bond market still struggles to ... 3 No-Brainer Dividend Growth Stocks to Buy in June

Johnson & Johnson (NYSE:JNJ) has announced positive findings from its Phase 2/3 ENERGY clinical trial, with IMAAVY (nipocalimab-aahu) demonstrating statistically significant improvements in hemoglobin levels among patients with warm autoimmune hemolytic anemia compared with placebo. The results provide further support for the therapy as the company seeks regulatory approval for a condition that currently has no FDA-approved treatment options.

As medtech companies eye entry into the IVL space, Shockwave Medical is consolidating its position through innovation and ongoing data generation.

A retired couple with a $2 million dividend-focused portfolio yielding roughly 6%, or $120,000 per year, watched their income stream fall by $14,400 during a difficult market period as covered-call funds, mortgage REITs, and business development companies trimmed distributions. Their annual income dropped to $105,600. They did not sell a share. Understanding why they were ... A $2 Million Dividend Portfolio Cut Its Distribution by $14,400 in One Year and the Holders Did Not Sell

Intravascular lithotripsy (IVL) has experienced strong uptake since Shockwave Medical became the first to market in the space.

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) said it has activated the first clinical site for its first-in-patient POLB 001 TOPICAL trial, moving its lead cancer immunotherapy programme into patient recruitment as interim data remains on track for summer 2026. The AIM-listed company...

Johnson & Johnson (JNJ) is one of the biggest names in health care, and lately, its stock has been living up to the hype. Shares have climbed back toward record territory, while much of the market has been affected by a sharp sell-off in technology stocks. Now, the company is pumping fresh cash ...